The Market for Metabolic Syndrome Therapies is Forecast to Increase from $9.7 Billion in 2003 to $12.8 Billion in 2013

Research and Markets (http://www.researchandmarkets.com/reports/c32025) has announced the addition of Barriers to Effective Management of Metabolic Syndrome to their offering.

This Decision Resources report forecasts that the market for metabolic syndrome therapies will increase from $9.7 billion in 2003 to $12.8 billion in 2013. This market has enormous untapped potential, especially in Europe, but several major barriers (e.g., a lack of consensus on the definition of the disease, underdiagnosis, poor management, difficulties in the licensing of new therapies, reimbursement restrictions) have constrained growth.

In this Decision Resources report, the problems resulting from the lack of a consensus definition of metabolic syndrome are considered. The report then examines how limited knowledge and inadequate screening have contributed to underdiagnosis of the disease. It reviews therapeutic options and assesses the reimbursement environment for metabolic syndrome therapeutics. Further, the report analyzes the challenges that face drugs in development for this disorder and the consequences of a renewed debate over the validity of metabolic syndrome as a distinct disease. The report concludes with an assessment of the outlook and implications for the pharmaceutical industry.

Sedentary lifestyles and a steady increase in obesity have contributed to rapid growth in the prevalence of metabolic syndrome in many developed nations. It is estimated that, in 2003, almost 123 million people had metabolic syndrome in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. This population is projected to grow to 137 million in 2013. It is forecast that the market for metabolic syndrome therapies will increase from $9.7 billion in 2003 to $12.8 billion in 2013. The market has enormous untapped potential, especially in Europe, but several major barriers (e.g., a lack of consensus on the definition of the disease, underdiagnosis, poor management, difficulties in the licensing of new therapies, reimbursement restrictions) have constrained growth.

General practitioners (GPs) in Europe favor the use of lifestyle modifications in the treatment of metabolic syndrome. One survey found that 88% of GPs in the United Kingdom and 69% in France identified physical exercise or diet as a preferred treatment for this disorder. More than 70% of GPs in the United Kingdom also favored treatment of cholesterol or triglycerides, hypertension, overweight, or all factors, and 60% favored the use of oral antidiabetics in the management of metabolic syndrome. French GPs were markedly less inclined to use these therapeutic options. Moreover, GPs in the United Kingdom described an average of 4.7 of these options as preferred courses of action, compared with an average of just 2.0 for French GPs.

Physicians in the United States identify controlling hypertension and elevated low-density lipoprotein (LDL) cholesterol as top clinical priorities owing to the well-characterized cardiovascular risk associated with these abnormalities and the availability of effective agents that can regulate them. Common first-line therapy includes oral antidiabetic agents, antihypertensive agents, and statins to control each of these components. Physicians attach less importance to elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, and obesity, likely because the connection between these disorders and elevated cardiovascular risk is less clear and because therapeutic options are limited.

Achieving a consensus definition of metabolic syndrome would increase detection rates, stimulate the development of drugs targeted at metabolic syndrome, and improve the reimbursement climate for drugs prescribed for this indication. Recent convergence in definitions suggests that a consensus may be within reach, but two very influential associations have challenged the validity of the concept of metabolic syndrome. If other organizations support this view, and the medical profession responds to such advice, the concept of metabolic syndrome as a distinct disease could fall out of favor.

Some of the most widely prescribed drugs for constituents of the metabolic syndrome (e.g., metformin, glibenclamide, simvastatin, lovastatin, pravastatin, ramipril, amlodipine) are off-patent in Europe, and many other agents will lose patent protection in the next five to ten years. As a result, the European market for metabolic syndrome therapies is becoming increasingly genericized. With one or more oral antidiabetics, statins, and antihypertensives available in generic form in most of Europe, physicians can manag most of the symptoms of metabolic syndrome without prescribing branded medicines.

For more information visit http://www.researchandmarkets.com/reports/c32025

Laura Wood
Senior Manager
Research and Markets
press-at-researchandmarkets.com
Fax: +353 1 4100 980




The Market for Metabolic Syndrome Therapies is Forecast to Increase from $9.7 Billion in 2003 to $12.8 Billion in 2013



***Note This page is an Archieve of Publicly released information either through our company or another Press Release organization. We do not "fact check", "Support", nor "Dispute" any of the information provided to us. We are a distribution point and Historical press release research and search service. This information only represents the fact that at one point in time the release was distributed to 1000's of publications both online and off. PRNewsNow will not take sides in any personal or commercial disputes you have with the writer of this press release. We will defend its right to exist blindly and without regards to its political, commercial or personal implications.***